E. L. Korn, P-Y Liu, S. J. Lee, J-A W. Chapman, D. Niedzwiecki, V. J. Suman, J. Moon, V. K. Sondak, M. B. Atkins, E. A. Eisenhauer, W. Parulekar, S. N. Markovic, S. Saxman and J. M. Kirkwood, “Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials,” Journal of Clinical Oncology, Vol. 26, No.4, 2008, pp 527-534.
 A. Y. Bedikian, M. Millward, H. Pehamberger, R. Conry, M. Gore, U. Trefzer, A. C. Pavlick, R. DeConti, E. M. Hersh, P. Hersey, J. M. Kirkwood and F. G. Haluska “Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group,” Journal of Clinical Oncology, Vol. 24, No.29, 2006, pp 4738-4745.
 P. Hersey, S. W. Menzies, G. M. Halliday, T. Nguyen, M. L. Farrelly, C. DeSilva and M. Lett “Phase I/II Study of Treatment with Dendritic Cell Vaccines in Patients with Disseminated Melanoma,” Cancer Immunol Immunother, Vol. 53, No.2, 2004, pp 125-34.
 P. Hersey, A. S. Coates, W. H. McCarthy, J. F. Thompson, R. W. Sillar, R. McLeod, P. G. Gill, B. J. Coventry, A. McMullen, H. Dillon and R. J. Simes, “Adjuvant Immunotherapy of Patients with High-risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial,” Journal of Clinical Oncology, Vol. 20, No.20, 2002, pp 4181-90.
 M. F. Avril, S. Aamdal, J. J. Grob, A. Hauschild, P. Mohr, J. J. Bonerandi, M. Weichenthal, K. Neuber, T. Bieber, K. Gilde, V. Guillem Porta, J. Fra, J. Bonneterre, P. Sa?ag, D. Kamanabrou, H. Pehamberger, J. Sufliarsky, J. L. Gonzalez Larriba, A. Scherrer and Y. Menu “Fotemustine Compared with Dacarbazine in Patients with Disseminated Malignant Melanoma: a Phase III Study,” Journal of Clinical Oncology, Vol. 22, No.6, 2004, pp 1118-25.
 I. Quirbt, S. Verma, T. Petrella, K. Bak, M. Charette and the members of the Melanoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care, “Temozolomide for the Treatment of Metastatic Melanoma” Current Oncology, Vol. 14,No.1, 2007, pp 27-33.
 E. C. Hsueh, R. Essner, L. J. Foshag, D. W. Ollila, G. Gammon, S. J. O'Day, P. D. Boasberg, S. L. Stern, Y. Xe and D. L. Morton, “Prolonged Survival after Complete Resection of Disseminated Melanoma and Active Immunotherapy with a Therapeutic Cancer Vaccine,” Journal of Clinical Oncology, Vol. 20,No.23, 2002, pp 4549-54.
 A. K. Nowak, B. W. Robinson and R. A. Lake, “Synergy between Chemotherapy and Immunotherapy in the Treatment of Established Murine Solid Tumors,” Cancer Research, Vol. 63, No.15, 2003, pp 4490-6.
 J. Taieb, N. Chaput, N. Schartz, S. Roux, S. Novault, C. Ménard, F. Ghiringhelli, M. Terme, A. F. Carpentier, G. Darrasse-Jèze, F. Lemonnier and L. Zitvogel, “Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines,” Journal of Immunology, Vol. 176, No.5, 2006, pp 2722-9.
 B. J. Coventry, M. L. Ashdown, M. A. Quinn, S. N. Markovic, S. L. Yatomi-Clarke, A. P. Robinson, “CRP Identifies Homeostatic Immune Oscillations in Cancer Patients: A Potential Treatment Targeting Tool?” Journal of Translational Medicine, Vol. 7, 2009, pp 102-109
 B. J. Coventry, J. M. Austyn, S. Chryssidis, D. Hankins and A. Harris, “Identification and Isolation of CD1a Positive Putative Tumour Infiltrating Dendritic Cells in Human Breast Cancer,” Advances in Experimental Medicine and Biology, Vol. 417, 1997, pp 571-7.
 E. E. Hillenbrand, A. M. Neville and B. J. Coventry, “Immunohistochemical Localization of CD1a-positive Putative Dendritic Cells in Human Breast Tumours,” British Journal of Cancer, 79(5-6), 1999, pp 940-4.
 B. J. Coventry, P. L. Lee, D. Gibbs and D. N. Hart, “Dendritic Cell Density and Activation Status in Human Breast Cancer -- CD1a, CMRF-44, CMRF-56 and CD-83 expression,” British Journal of Cancer, Vol.86, No.4, 2002, pp 546-51.
 A. H. Barbour and B. J. Coventry, “Dendritic Cell Density and Activation Status of Tumour Infiltrating Lymphocytes in Metastatic Human Melanoma: Possible Implications for Sentinel Node Metastases,” Melanoma Research, Vol. 13, No.3, 2003, pp 263-269.
 N. Chaput, G. Darrasse-Jèze, A. S. Bergot, C. Cordier, S. Ngo-Abdalla, D. Klatzmann, “Azogui O Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites,” Journal of Immunology, Vol. 179, No.8, 2007, pp 4969-78.
 S. Nizar, J. Copier, B. Meyer, M. Bodman-Smith, C.Galustian, D. Kumar and A. Dalgleish, “T-regulatory cell modulation: the future of cancer immunotherapy?” Minireview British Journal of Cancer, Vol. 100, 2009, pp 1697-1703.
 B. J. Coventry, S. C. Weeks, S. E. Heckford, P. J. Sykes, J. Bradley and J. M. Skinner, “Lack of IL-2 Cytokine Expression despite Il-2 Messenger RNA Transcription in Tumor Infiltrating Lymphocytes in Primary Human Breast Carcinoma: Selective Expression of Early Activation Markers,” Journal of Immunology, Vol.156, No.9, 1996, pp 3486-92.
 N. G. Chakraborty, S. Chattopadhyay, S. Mehrotra, A. Chhabra and B. Mukherji, “Regulatory T-cell Response and Tumor Vaccine-induced Cytotoxic T Lymphocytes in Human Melanoma,” Human Immunology, Vol.65, No.8, 2004, pp 794-802.
 G. Darrasse-Jèze, A. S. Bergot, A. Durgeau, F. Billiard, B. L. Salomon, J. L. Cohen, B. Bellier, K. Podsypanina and D. Klatzmann, “Tumor Emergence is Sensed by Self-specific CD44hi Memory Tregs that Create a Dominant Tolerogenic Environment for Tumors in Mice,” Journal of Clinical Investigation, Vol. 119, No.9, 2009, pp 2648-62.
 G. Darrasse-Jèze, S. Deroubaix, H. Mouquet, D. Victora, T. Eisenreich, K. H. Yao, R. F. Masilamani, M. L. Dustin, A. Rudensky, K. Liu and M. C. Nussenzweig, “Feedback Control of Regulatory T Cell Homeostasis by Dendritic Cells in Vivo,” Journal of Experimental Medicine, Vol. 206, No.9, 2009, pp 1853-62.